Stereotactic body radiation therapy for sarcoma pulmonary metastases
暂无分享,去创建一个
W. Tap | A. Rimner | A. Wu | D. Gelblum | M. Dickson | K. Alektiar | B. Nacev | E. Lebow | C. Simone II | A. Shepherd | N. Shaverdian | S. D’Angelo | D. Gómez | S. Lobaugh | E. Rosenbaum | S. Wolden | Zhigang Zhang
[1] Narasimhan P. Agaram,et al. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma , 2022, Nature Communications.
[2] Narasimhan P. Agaram,et al. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma , 2022, Nature Communications.
[3] S. Singer,et al. Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] Narasimhan P. Agaram,et al. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets , 2021, Nature Communications.
[5] Jacob G. Scott,et al. Safety of Metastasis-Directed SBRT and Concurrent Pazopanib in Pediatric Sarcoma , 2020 .
[6] Kevin B. Jones,et al. The epigenomics of sarcoma , 2020, Nature Reviews Cancer.
[7] I. Shin,et al. Benefits of local consolidative treatment in oligometastases of solid cancers: a stepwise-hierarchical pooled analysis and systematic review , 2020, npj Precision Oncology.
[8] C. Simone,et al. Multi‐institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity , 2020, Journal of surgical oncology.
[9] B. Yaremko,et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial , 2019, BMC Cancer.
[10] J. Lee,et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Riedel,et al. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma , 2018, Cancer.
[12] J. Galvin,et al. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial , 2018, JAMA oncology.
[13] J. Galvin,et al. Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non–Small Cell Lung Cancer , 2018, JAMA oncology.
[14] E. Yorke,et al. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC) , 2018, Acta oncologica.
[15] D. Kirsch,et al. Multidisciplinary Management of Oligometastatic Soft Tissue Sarcoma. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[16] C. Antonescu,et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. , 2018, The Lancet. Oncology.
[17] J. Crowley,et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. , 2017, The Lancet. Oncology.
[18] B. Corn,et al. Single-institution Experience of SBRT for Lung Metastases in Sarcoma Patients , 2017, American journal of clinical oncology.
[19] J. Lee,et al. Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.
[20] L. Uhlmann,et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy". , 2016, Lung cancer.
[21] K. Rosenzweig,et al. Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance. , 2016, Clinical lung cancer.
[22] N. Araki,et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study , 2016, Cancer.
[23] E. Yorke,et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. , 2016, Practical radiation oncology.
[24] A. Chaudhuri,et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. , 2015, Lung cancer.
[25] H. Gelderblom,et al. Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series , 2014, Clinical Sarcoma Research.
[26] E. Yorke,et al. Stereotactic Body Radiation Therapy for Primary Lung Cancers >3 Centimeters , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[27] J. Blay,et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.
[28] Wen Gao,et al. Local extension at the hilum region is associated with worse long-term survival in stage I non-small cell lung cancers. , 2012, The Annals of thoracic surgery.
[29] H. Ott,et al. Pulmonary resection of metastatic sarcoma: prognostic factors associated with improved outcomes. , 2011, The Annals of thoracic surgery.
[30] J. Wunder,et al. Soft tissue sarcoma presenting with metastatic disease , 2011, Cancer.
[31] S. Siva,et al. Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[32] J. Roth,et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. , 2009, The Annals of thoracic surgery.
[33] R. Grimer,et al. Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas. , 2008, European journal of cancer.
[34] E. Yorke,et al. High-Dose Radiotherapy for the Treatment of Inoperable Non–Small Cell Lung Cancer , 2007, Cancer journal.
[35] Samuel Ryu,et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. , 2004, International journal of radiation oncology, biology, physics.
[36] M. Ferguson,et al. Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. , 2003, The Annals of thoracic surgery.
[37] C C Ling,et al. The deep inspiration breath-hold technique in the treatment of inoperable non-small-cell lung cancer. , 2000, International journal of radiation oncology, biology, physics.
[38] M. Burt,et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. , 1999, Annals of surgery.
[39] D H Leung,et al. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma , 1999, Cancer.
[40] S. Rosenberg,et al. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] W. Franklin,et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.